Evidence map›Paper›PMID 41354787›Full record

ArticleBMC infectious diseases2025

HMGB1 and metabolic pathways in Acinetobacter baumannii pneumonia: an associative study.

Mingshan Xue, Zhiwei Lin, Teng Zhang, Qianyue Yang, Ning Li, Zhangkai Jason Cheng, Shaohui Fan, Youxia Li, Lijun Su, Baojun Guo and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mingshan Xue *National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Zhiwei Lin *National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Teng Zhang *China Institute for Radiation Protection, Taiyuan, China.
Qianyue YangNational Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Ning LiNational Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Zhangkai Jason ChengNational Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Shaohui FanThe Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China.
Youxia LiThe Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China.
Lijun SuNational Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Baojun GuoNational Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Runpei LinNational Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China.
Zhiping DengZigong First People's Hospital, Zigong, Sichuan, China.
Yueting JiangDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Lin YuDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Youli WenZigong First People's Hospital, Zigong, Sichuan, China. 165178713@qq.com.
Hongman WangThe Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, China. 2496453591@qq.com.
Baoqing SunNational Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institue of Respiratory Health, Guangzhou, 510120, China. sunbaoqing@vip.163.com.

Funding

Chinese National Natural Science Foundation 81960023
6 · The paper itself

Abstract

backgroundAcinetobacter baumannii (AB) pneumonia often leads to lung injury and multisystem dysfunction. High Mobility Group Box 1 (HMGB1) is known to play a crucial role in the progression of AB. In this study, we aimed to investigate the association between HMGB1 levels and the severity of AB pneumonia.

methodsWe conducted a study with a total of 91 participants, divided into three groups: patients with AB infection (n = 44), patients with AB complicated multiple organ disfunctions (MODs) (n = 19), and healthy controls (n = 28). Clinical parameters were assessed, HMGB1 levels were measured, and metabolomic analysis was performed. Validation experiments were conducted using SD rats.

resultsPatients with AB exhibited significantly elevated levels of HMGB1. In the multi-organ failure group, neutrophils, monocytes, and HMGB1 levels were higher, while lymphocytes were reduced. Metabolomic analysis revealed 28 metabolites correlated with HMGB1, among which 12-HPETE, asparagine, lactic acid, and carbamyl-aspartate showed the most notable changes. These representative metabolites reflect HMGB1-associated shifts in inflammation and energy metabolism. HMGB1 elevation was further confirmed in SD rats, and its blockade alleviated lung inflammation. Consistently, C-reactive protein (CRP) and procalcitonin (PCT) levels were also increased, supporting the link between HMGB1 and systemic inflammation.

conclusionHMGB1 levels rise sharply in AB pneumonia-especially in patients with MODs-and correlate with inflammatory and hypoxic metabolic shifts. Anti-HMGB1 treatment in SD rats reduced lung inflammation and injury, highlighting HMGB1's potential as a diagnostic biomarker and therapeutic target.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsHMGB1 ProteinMetabolic Networks and PathwaysPneumonia, BacterialAdultAgedAnimalsBiomarkersC-Reactive ProteinFemaleHumansMaleMetabolomicsMiddle AgedRatsBiomarkersC-Reactive ProteinHMGB1 ProteinHMGB1 protein, humanAcinetobacter baumanniiHMGB-1Lung injury.MetabolomicsMODs

Identifiers

PMID41354787
PMCPMC12809963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.